An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Clinical trial NCT00171158 · COMPLETED
Trial details
- NCT number
- NCT00171158
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 1999-07-26
- Primary completion
- 2013-04-01
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.